En bref : Boehringer Ingelheim, Bioxodes, EuroAPI

2023-11-23 15:00:00

Oncologie : Boehringer Ingelheim s’offre T3 Pharma pour 467 M€

The German laboratory announced the acquisition of the Swiss biotech company specializing in immuno-oncology, T3 Pharma. To do this, Boehringer Ingelheim will spend 450 million Swiss francs (€467 million). Founded in 2015, T3 Pharma has developed a platform using bacteria Yersinia enterocolitica which selectively delivers immunomodulatory proteins into the tumor microenvironment, while sparing healthy tissues. The biotech has four programs in development in its pipeline, the most advanced being in phase I.

“The acquisition of T3 Pharma will significantly expand our immuno-oncology pipeline portfolio and is synergistic with many of our existing R&D programs. This will bring us closer to realizing our vision of bringing about a paradigm shift in cancer treatments”said Michel Pairet, member of the board of directors of Boehringer Ingelheim and head of the innovation unit.

VOS INDICES

Bioxodes raises €12 million

During a Series A financing round, the Belgian biotech specializing in thrombo-inflammatory diseases, Bioxodes, raised the sum of 12 million euros. With these funds, it intends to continue the development of its main compound, Ir-CPI. This drug candidate first-in-class is currently evaluated in phase IIa in intracerebral hemorrhage. Recruitment of the first patient in this study is planned before the end of the last quarter of 2023. Bioxodes also hopes to develop its preclinical pipeline. Since its creation in 2013, the biotech has raised a total of €39 million.

CDMO: EuroAPI finalizes the acquisition of Biano

EuroAPI announced the finalization of the acquisition of the German company Biano, for an amount of approximately ten million euros. Founded in 2017, Biano specializes in oligonucleotides, small fragments of DNA or RNA capable of acting on gene expression. A market in which CDMO is already positioned, particularly on its site in Frankfurt, Germany. As planned, Biano will retain its commercial brand name and become a EuroAPI company.

Selected for you

Oncology: Ose Immunotherapeutics to collaborate with GenDx for a companion test

1700796006
#bref #Boehringer #Ingelheim #Bioxodes #EuroAPI

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.